Leptin is a multifunctional hormone that's produced by adipose tissue and leptin is involved in the regulation of food intake and energy balance. The aims of this study were to determine the leptin and leptin receptor (Ob-R) expressions in human breast cancer and their corresponding influence on the prognosis of patients with breast cancer.
I n t r o d u c t i o n
Obesity is an important and manageable risk factor for the development and progression of postmenopausal breast cancer (1) . There is evidence suggesting that the increased production and secretion of adipocyte-derived growth factors and hormones contribute to cellular transformation and tumorigenesis (2, 3) . Leptin is required for the breast's normal mammary gland development and lactation, but leptin might also contribute to mammary tumorigenesis (4) . It has been previously shown that leptin and leptin receptor (Ob-R) are overexpressed in primary and metastatic invasive ductal breast carcinoma as compared to that of healthy mammary tissues (5) .
Leptin is a product of the obese (ob) gene, and leptin is an adipocytokine that regulates appetite, bone formation, reproduction, cellular proliferation and angiogenesis (6) . Several actions of leptin, including the stimulation of normal and tumorous cell growth, migration, invasion and enhancement of angiogenesis, suggest that this hormone can promote an aggressive breast cancer phenotype that is estrogen-independent (7) .
In vitro studies have demonstrated that leptin stimulates the growth, survival and transformation of breast cancer cells (4) , and it does so primarily by activating the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway (8, 9) Cancer Res Treat and the phosphoinositol-3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) pathways (10) .
We studied the correlations between the immunohistochemical expression of leptin/Ob-R and the breast cancer-related prognostic variables, and we analyzed their correlations with overall survival and relapse-free survival (RFS) in 517 patients with breast cancer.
M a t e r i a l s a n d M e t h o d s

Patients
Five hundred seventeen patients (median age: 46 years, age range: 23�84 years) with breast carcinomas were included in this study. The patients underwent breast cancer surgery at the National Cancer Center (Goyang, Korea) and at Kangbuk Samsung Hospital (Seoul, Korea) between 2000 and 2006. Three hundred fifty-two of the patients with breast cancer underwent survival analysis. The mean follow-up was 53 months (range: 7�85 months). The immunohistochemical expression of leptin/Ob-R was analyzed in the 517 patients with breast cancer. The RFS was calculated as the period from surgery until the date of the first tumor recurrence. This study was submitted to and met the guidelines of the local institutional review committees.
A standard histopathologic examination was done that included determining the type of cancer and the pathologic tumor stage, which were assessed according to the criteria established by the 6 th edition AJCC staging manual (11) . Forty-six of the 517 patients (9%) had in situ carcinoma. The histologic types of invasive cancers were mucinous carcinoma (n=8), medullary carcinoma (n=3), metaplastic carcinoma (n=1), tubulolobular carcinoma (n=1), lobular carcinoma (n=1) and ductal not otherwise specified (NOS; n=457).
H&E and immunohistochemical staining
All of the tissues obtained from the patients were routinely fixed in 10% buffered formalin and then they were embedded in paraffin blocks. The tissue array blocks containing the breast cancer tissues (tissue cores 6 mm in diameter) were produced from the enrolled cases. The tissue microarray blocks were sectioned at a 4-μ m thickness and these were processed for immunohistochemical staining. The paraffin was removed from the tissue sections with xylene. The sections were rehydrated in a graded series of ethanol solutions and then the sections were immersed in Tris-buffered saline. The expressions of leptin and Ob-R were investigated by immunohistochemical staining with using rabbit polyclonal antibodies against leptin (A20, 1 : 00 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and goat polyclonal antibodies against Ob-R (M-18, 1 : 30 dilution; Santa Cruz Biotechnology). A biotinylated anti-mouse antibody was used as a secondary antibody, and streptavidin horseradish peroxidase (Zymed Laboratories, San Francisco, CA) was used following the instructions provided by the manufacturer. The sections were counterstained in Mayer's hematoxylin; they were then dehydrated and cleared, and the sections were mounted for examination.
Interpretation of the immunohistochemistry findings
The immunohistochemical expression was evaluated as the percentage of the cells that had cytoplasmic staining for leptin and membranous staining for Ob-R with any intensity. The expression was scored as positive if ＞5% of the cells were reactive with any intensity (4) .
A cutoff value of 10% for the positively stained nuclei was used to define positivity for estrogen receptor (ER) and progesterone receptor (PR). Cytoplasmic staining with any intensity in ＞10% of the tumor cells was scored as positive for Bcl-2. Membranous staining for HER2 was scored as follows: 0, no staining or membranous staining in ＜10% of the cells; 1+, faint incomplete staining in 10% of the cells; 2+, weak-to-moderate complete staining in 10% of the cells; and 3+, strong complete staining in1 0% of the cells. An HER2 overexpression was defined as a score of 3+. The cells that stained for Ki-67 and p53 were expressed as a percentage. The Ki-67 labeling index was graded as low if the number of positive cells was ＜10% and high if the number of positive cells was ≥10%. The staining for p53 was scored as positive if ＞10% of the cells were positive with a strong intensity.
Statistical analysis
Statistical analysis was performed with using SPSS software, version 15.0 (SPSS, Inc., Chicago, IL). Pearson's χ 2 test was used to examine the correlation between the variables. The Kaplan-Meier curves were plotted from the data of the overall survival and the RFS. We estimated the hazard ratios along with the 95% CIs for assessing the association of the leptin expression and the Ob-R expression with overall survival and RFS by using the Cox proportional hazards model, with adjustment for the tumor size (≤2 cm or ＞2 cm), the nodal status (negative or positive), the hormone receptor status (negative or positive), chemotherapy (yes or no) and hormone therapy (yes or no). A p-value＜0.05 was considered to be statistically significant.
R e s u l t s 1 Clinicopathologic correlation of the leptin expression and the Ob-R expression in the breast cancer tissues
The clinicopathologic characteristics of the enrolled patients are shown in Table 1 . Positive cytoplasmic immunoreactivity for leptin was found in 39% of the cases (190 of 490). Positive cytomembranous staining for Ob-R was noted in 78% of the cases (369 of 473; Fig. 1 , Table 2 ).
Neither the leptin expression nor the Ob-R expression had a significant correlation with age, the BMI, the histologic grade, the T stage, the N stage or the AJCC staging. The expression of leptin in breast cancer was correlated with a high Ki-67 labeling index (p=0.019). The rate of the leptin expression was significantly higher for the breast cancers of the triple negative (TN) type than that for the non-TN type (p=0.022). Although there was no statistical significance, the rate of a leptin expression was higher for the breast cancers that had no expression of hormone receptors (p=0.08), no p53 overexpression (p=0.08) and no bcl-2 expression (p=0.38). The rate of an Ob-R expression was higher for the non-TN breast cancers (p=0.045) and the breast cancers with a high Ki-67 labeling index (p=0.06; Table 2 ).
We categorized the leptin/Ob-R expression into leptin+/Ob-R+, leptin+/Ob-R-, leptin-/Ob-R+ and leptin-/Ob-R-. The leptin+/Ob-R+ breast cancers showed a tendency to have a higher Ki-67 labeling index than did the other groups (p=0.014; 
Survival analysis for the leptin expression and the Ob-R expression in the breast cancer patients
Based on the univariate Kaplan-Meier analysis of all 352 cases for the overall survival, the clinicopathologic variables with prognostic value included the histologic grade, the T stage, the N stage, the HER2 status and a Ki-67 expression (p＜0.05; Table 4 ). No significant difference in overall survival was noted between the leptin-negative and leptin-positive groups or the Ob-R-negative and Ob-R-positive groups. Based on a stratified analysis by the hormone receptor status, the patients who had breast cancer with a negative hormone receptor status and a leptin expression had a longer overall survival than the patients who had breast cancer with a negative hormone receptor and no leptin expression (Fig. 2B, Table 5 ). Based on the univariate Kaplan-Meier analysis of all 352 cases for RFS, the clinicopathologic variables with prognostic value included the T stage, the N stage, the HER2 status and a p53 expression (p＜0.05; node status and the hormone receptor status were significant independent factors that affected overall survival; the lymph node status was a significant independent factor affecting RFS in a model with variables that included the tumor size, the lymph node status, the hormone receptor status, a leptin expression and a Ob-R expression ( Table 7 . Kaplan-Meier survival analysis for adjuvant therapy in leptin-positive and leptin-negative breast cancer chemotherapy and hormone therapy, the patients with leptinpositive breast cancer had a hazard ratio for overall survival of 0.20 (95% CI, 0.04 to 0.99; p=0.05).
Benefit of chemotherapy for the leptin-positive group
The correlation of the benefit of adjuvant therapy and a leptin expression was studied by performing Kaplan-Meier analysis on the leptin-positive and leptin-negative groups ( Table 7) . The leptinpositive group patients showed a significant benefit from chemotherapy for RFS as compared to that of the leptin-negative group. However, no significant difference was noted between the leptin-negative and leptin-positive groups for hormone therapy.
D i s c u s s i o n
In our study of the immunohistochemical expression of the leptin/Ob-R system and the breast cancer-related prognostic variables, we observed a significant correlation between a leptin expression and the Ki-67 labeling index in breast cancers. There are previous in vitro studies that have demonstrated that leptin stimulates the proliferation of cancer cells (12) , it inhibits apoptosis (13) and it induces angiogenesis (14) . Leptin was recently reported to stimulate the proliferation of various types of tumor cells (prostate, colorectal and lung) (15) . Similar results have been described for breast cancer; leptin has been shown to stimulate the proliferation of breast cancer cell lines (16) . These mitogenic effects are directly related to the activation of the extracellular signalregulated kinase (ERK) and Akt signaling pathways, which are both involved in breast cancer cell proliferation. To date, the prevailing hypothesis has been that the effects of leptin are primarily mediated through the action of ERK signaling pathway. However, it has been suggested that leptin may stimulate the ER-negative breast cancer cells by altering the mitogenic signaling pathways to promote the pathogenesis of cancer (17) .
There are some reports regarding the correlation between the prognosis of breast cancers and the leptin expression and the Ob-R expression in breast cancer tissues (5, (18) (19) (20) . Miyoshi et al. (21) reported that a high expression of Ob-R mRNA in breast cancer tissue predicts a poor prognosis for the patients with high leptin levels in their sera. Revillion et al. (18) reported that an elevated messenger RNA expression of the short isoform of leptin receptor (OB-R-S) was associated with a shorter RFS.
In contrast, our results showed that the expression of leptin correlates with a better overall survival for patients with hormone receptor-negative breast cancers, but not for patients with hormone receptor-positive breast cancers. Our results showed that the leptinpositive breast cancer patients obtained significant benefit from chemotherapy for the RFS.
For colorectal adenocarcinoma, it has been reported that a leptin expression correlates with a favorable clinicopathologic phenotype and a better prognosis (22) . Our results showed that patients with leptin-positive breast cancer and who received chemotherapy had a survival benefit. It is possible that a leptin expression might positively influence the sensitivity to chemotherapy or radiotherapy during postoperative adjuvant treatment.
Limited studies on cancer and non-cancer breast biopsies have indicated that both leptin and Ob-R are present in human breast tissue, and this suggests that the mammary gland is influenced by leptin, not only through paracrine or endocrine mechanisms, but also via the autocrine pathways (4). Chen et al. (23) reported there was no significant effect of the surgical removal of tumors on the high serum leptin concentrations in breast cancer patients. This finding is consistent with the idea that production of leptin by tumor is a minor source of the adipokine, while the unexcised adipose tissue remains a major contributor to the circulating leptin levels (17) . Thus, a leptin expression in breast cancer tissue is considered to be a product of the paracrine pathway for the serum leptin that's produced in peritumoral adipose tissue with its release into the circulation. The paracrine relationship between the breast cancer cells and the surrounding breast adipose tissue appears to be more important in terms of bioregulatory effects than is a potential leptin-mediated autocrine loop (17) . There are some controversial reports concerned with the plasma and serum leptin concentrations and the risk of breast cancer (23, 24) , and so further studies on the circulating leptin concentrations in relation to the leptin expression in breast cancer tissue and the breast cancer risk are needed.
The completion of a paracrine loop requires the presence of a specific ligand-binding receptor on the target cell. The Ob-R occurs in multiple forms, and only one of these (the long form [LRb or OB-RI]) has an intracellular domain of sufficient length to provide for full signal-transducing capabilities (17) . In this study, we used the antibody against Ob-R, which detects the short and long forms of Ob-R of mouse, rat and human origins.
C o n c l u s i o n
The leptin expression and the Ob-R expression were closely associated with breast tumorigenesis. A leptin expression was significantly related to a high Ki-67 labeling index, and this suggests an important role for leptin in breast carcinogenesis. For the hormone receptor-negative breast cancers, a leptin expression in breast cancers was inversely correlated with the prognosis. These findings suggest that leptin may be an important prognostic marker for breast cancer in the hormone receptor-negative patients. Further studies are needed to understand the exact role of a leptin expression in breast cancer.
